PharmaRoth Labs Announces Approval Of Sucanon In Canada

LAS VEGAS, NV--(Marketwired - October 13, 2015) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that Sucanon® has been approved for over the counter sales in Canada as a natural health product. The approval comes through Health Canada, the regulating health-care agency of Canada.

“We are very excited that our product is expanding into the North American market. We expect this approval to open the door for countries around the world to accept Sucanon® as an effective solution to the global Type-II diabetes epidemic,” commented Luis Lopez, CEO of PharmaRoth. “Many countries look to the US, Canada and the EU for guidance in these matters, making this a landmark approval.

“This approval, along with our new retail relationship in Mexico, is the culmination of many months of hard work, and we feel that the Company is properly positioned for a new and more prosperous future.”

For further information regarding Health Canada, please visit: http://www.hc-sc.gc.ca/index-eng.php

About Sucanon®
Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called “insulin sensitizers.” Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit www.pharmaroth.com

About PharmaRoth
PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.